1. Home
  2. MBIO vs TOVX Comparison

MBIO vs TOVX Comparison

Compare MBIO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBIO
  • TOVX
  • Stock Information
  • Founded
  • MBIO 2015
  • TOVX 2001
  • Country
  • MBIO United States
  • TOVX United States
  • Employees
  • MBIO N/A
  • TOVX N/A
  • Industry
  • MBIO Biotechnology: Pharmaceutical Preparations
  • TOVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MBIO Health Care
  • TOVX Health Care
  • Exchange
  • MBIO Nasdaq
  • TOVX Nasdaq
  • Market Cap
  • MBIO 4.7M
  • TOVX 3.8M
  • IPO Year
  • MBIO N/A
  • TOVX 2006
  • Fundamental
  • Price
  • MBIO $1.24
  • TOVX $0.45
  • Analyst Decision
  • MBIO
  • TOVX Hold
  • Analyst Count
  • MBIO 0
  • TOVX 1
  • Target Price
  • MBIO N/A
  • TOVX N/A
  • AVG Volume (30 Days)
  • MBIO 1.6M
  • TOVX 279.2K
  • Earning Date
  • MBIO 08-12-2025
  • TOVX 08-12-2025
  • Dividend Yield
  • MBIO N/A
  • TOVX N/A
  • EPS Growth
  • MBIO N/A
  • TOVX N/A
  • EPS
  • MBIO N/A
  • TOVX N/A
  • Revenue
  • MBIO N/A
  • TOVX N/A
  • Revenue This Year
  • MBIO N/A
  • TOVX N/A
  • Revenue Next Year
  • MBIO N/A
  • TOVX N/A
  • P/E Ratio
  • MBIO N/A
  • TOVX N/A
  • Revenue Growth
  • MBIO N/A
  • TOVX N/A
  • 52 Week Low
  • MBIO $0.89
  • TOVX $0.40
  • 52 Week High
  • MBIO $31.00
  • TOVX $7.37
  • Technical
  • Relative Strength Index (RSI)
  • MBIO 50.75
  • TOVX 37.60
  • Support Level
  • MBIO $0.89
  • TOVX $0.42
  • Resistance Level
  • MBIO $2.13
  • TOVX $0.55
  • Average True Range (ATR)
  • MBIO 0.16
  • TOVX 0.03
  • MACD
  • MBIO 0.04
  • TOVX 0.02
  • Stochastic Oscillator
  • MBIO 28.05
  • TOVX 30.00

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: